© Reuters. FILE PHOTO; Valneva brand is seen displayed on this illustration taken, Could 3, 2022. REUTERS/Dado Ruvic/Illustration
PARIS (Reuters) – Vaccines firm Valneva stated on Friday that it had accomplished a regulatory submission step with america Meals & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.
Chikungunya is a mosquito-borne viral illness. Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe within the second half of 2023.